Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis.

BACKGROUND

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors show promising results in metastatic breast cancer. However, an increased incidence of adverse events is remarkable. Among others, gastrointestinal (GI) involvement is of momentous impact on patients and their quality of life.

METHODS

Our search included and databases. Randomized phase II/III trials in metastatic breast cancer receiving CDK4/6 inhibitors were identified and considered relevant based on providing a sufficient safety profile on the incidence of adverse GI effects.

RESULTS

Of the 999 records initially screened for relevance, 33 articles were found relevant and 4 studies were finally eligible for meta-analysis with a total of 2007 patients. The relative risk (RR) for all-grade nausea was 1.48 [95% confidence interval (CI): 1.12-1.93, = 0.005], vomiting was 1.74 (95% CI: 1.09-2.76, = 0.02), decreased appetite was 1.42 (95% CI: 1.07-1.88, = 0.02), and for diarrhea it was 1.44 (95% CI: 1.19-1.74, = 0.0002). Meanwhile, the RR for high-grade nausea was 1.10 (95% CI: 0.29-4.13, = 0.89), vomiting was 1.38 (95% CI: 0.25-7.75, = 0.72), decreased appetite was 4.00 (95% CI: 0.87-18.37, = 0.07), and high-grade diarrhea was 1.19 (95% CI: 0.44-3.21, = 0.73).

CONCLUSION

Selective CDK4/6 inhibitors were not associated with higher-grade GI toxicities reflecting a well-tolerated safety profile. Regarding the increase in all-grade GI toxicities, it needs further caution with addition of cytotoxic chemotherapy.